A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS) ; volume:24 ; number:1 ; day:13 ; month:11 ; year:2023 ; pages:1-11 ; date:12.2023
BMC pharmacology & toxicology ; 24, Heft 1 (13.11.2023), 1-11, 12.2023
- Creator
-
Zou, Shu-peng
Yang, Hai-yun
Ouyang, Meng-ling
Cheng, Qian
Shi, Xuan
Sun, Ming-hui
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40360-023-00702-w
- URN
-
urn:nbn:de:101:1-2024013013572033162281
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zou, Shu-peng
- Yang, Hai-yun
- Ouyang, Meng-ling
- Cheng, Qian
- Shi, Xuan
- Sun, Ming-hui
- SpringerLink (Online service)
Other Objects (12)
Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system
Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
Possible adverse events of imidazole antifungal drugs during treatment of vulvovaginal candidiasis: analysis of the FDA Adverse Event Reporting System
Standardizing adverse drug event reporting data
Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System
A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database
Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal and conventional doxorubicins
Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system
Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
Possible adverse events of imidazole antifungal drugs during treatment of vulvovaginal candidiasis: analysis of the FDA Adverse Event Reporting System
Standardizing adverse drug event reporting data
Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System
A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database
Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal and conventional doxorubicins
Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system
Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
Possible adverse events of imidazole antifungal drugs during treatment of vulvovaginal candidiasis: analysis of the FDA Adverse Event Reporting System
Standardizing adverse drug event reporting data
Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System
A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database
Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system